LY2940680

Taladegib (LY2940680) is an antagonist of the smoothened receptor.

Taladegib has been used in trials studying the treatment of Solid Tumor, COLON CANCER, BREAST CANCER, Advanced Cancer, and Rhabdomyosarcoma, among others.|Taladegib is an orally bioavailable small molecule antagonist of the Hedgehog (Hh)-ligand cell surface receptor smoothened (Smo) with potential antineoplastic activity. Taladegib inhibits signaling that is mediated by the Hh pathway protein Smo, which may result in a suppression of the Hh signaling pathway and may lead to the inhibition of the proliferation of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation and has been observed in a variety of cancers.

Smoothened (Smo) is a GPCR-like receptor that, with Patched, mediates hedgehog (Hh) signaling to regulate gene expression through the Gli transcription factors. LY2940680 is an antitumor agent that binds to the human Smo receptor and inhibits Sonic Hh-induced Gli1 expression (IC50 = ~2.4 nM in vitro). The potential anticancer activity of LY2940680 is currently under clinical investigation.[Cayman Chemical]

Molecular Weight:512.5
XLogP3:4.3
Hydrogen Bond Acceptor Count:9
Rotatable Bond Count:4
Exact Mass:512.19477206
Monoisotopic Mass:512.19477206
Topological Polar Surface Area:67.2
Heavy Atom Count:37
Complexity:794
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes